» Articles » PMID: 21697511

Cyclin-dependent Kinase Subunit (Cks) 1 or Cks2 Overexpression Overrides the DNA Damage Response Barrier Triggered by Activated Oncoproteins

Overview
Specialty Science
Date 2011 Jun 24
PMID 21697511
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclin-dependent kinase subunit (Cks) proteins are small cyclin-dependent kinase-interacting proteins that are frequently overexpressed in breast cancer, as well as in a broad spectrum of other human malignancies. However, the mechanistic link between Cks protein overexpression and oncogenesis is still unknown. In this work, we show that overexpression of Cks1 or Cks2 in human mammary epithelial and breast cancer-derived cells, as well as in other cell types, leads to override of the intra-S-phase checkpoint that blocks DNA replication in response to replication stress. Specifically, binding of Cks1 or Cks2 to cyclin-dependent kinase 2 confers partial resistance to the effects of inhibitory tyrosine phosphorylation mediated by the intra-S-phase checkpoint, allowing cells to continue replicating DNA even under conditions of replicative stress. Because many activated oncoproteins trigger a DNA damage checkpoint response, which serves as a barrier to proliferation and clonal expansion, Cks protein overexpression likely constitutes one mechanism whereby premalignant cells can circumvent this DNA damage response barrier, conferring a proliferative advantage under stress conditions, and therefore contributing to tumor development.

Citing Articles

CKS2 induces autophagy-mediated glutathione metabolic reprogramming to facilitate ferroptosis resistance in colon cancer.

Yang L, Fang C, Han J, Ren Y, Yang Z, Shen L Mol Med. 2024; 30(1):219.

PMID: 39548421 PMC: 11568617. DOI: 10.1186/s10020-024-00979-5.


Biological functions and therapeutic potential of CKS2 in human cancer.

Lai Y, Lin Y Front Oncol. 2024; 14:1424569.

PMID: 39188686 PMC: 11345170. DOI: 10.3389/fonc.2024.1424569.


Global trends and hotspots in Cyclin-dependent Kinase Subunit 2 research from 1999 to 2022: A bibliometric and visualized analysis.

Li Z, Chen Y, Zhang B, Xie L, Shi B Medicine (Baltimore). 2023; 102(48):e36319.

PMID: 38050288 PMC: 10695487. DOI: 10.1097/MD.0000000000036319.


Identification of as a novel prognostic biomarker and potential therapeutic target for oral squamous cell carcinoma.

Qiu D, Cai H, Liang J, Wang Z, Song F, Jiang Y Transl Cancer Res. 2023; 12(9):2276-2293.

PMID: 37859732 PMC: 10583009. DOI: 10.21037/tcr-23-511.


Comprehensive analysis of the progression mechanisms of CRPC and its inhibitor discovery based on machine learning algorithms.

Wang Z, Zou J, Zhang L, Liu H, Jiang B, Liang Y Front Genet. 2023; 14:1184704.

PMID: 37476415 PMC: 10354439. DOI: 10.3389/fgene.2023.1184704.


References
1.
Inui N, Kitagawa K, Miwa S, Hattori T, Chida K, Nakamura H . High expression of Cks1 in human non-small cell lung carcinomas. Biochem Biophys Res Commun. 2003; 303(3):978-84. DOI: 10.1016/s0006-291x(03)00469-8. View

2.
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C . Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006; 444(7119):638-42. DOI: 10.1038/nature05327. View

3.
Bartek J, Lukas J . Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol. 2001; 13(6):738-47. DOI: 10.1016/s0955-0674(00)00280-5. View

4.
Merrick C, Jackson D, Diffley J . Visualization of altered replication dynamics after DNA damage in human cells. J Biol Chem. 2004; 279(19):20067-75. DOI: 10.1074/jbc.M400022200. View

5.
Su A, Welsh J, Sapinoso L, Kern S, Dimitrov P, Lapp H . Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001; 61(20):7388-93. View